BRCA1, a potential biomarker in the treatment of breast cancer

Colin James, Jennifer O'Brien, Paul Mullan, Patrick Johnston, Paul Harkin

Research output: Contribution to journalArticlepeer-review

144 Citations (Scopus)


To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of preclinical and retrospective clinical data has accumulated that suggests that BRCA1 mutation functions as a novel predictive marker of response to chemotherapy. This article reviews the role of BRCA1 as a predictive marker of chemotherapy response in breast cancer and examines the link between BRCA1 deficiency and the basal-like phenotype. Search strategy. Data for this article were identified through MEDLINE and PubMed searches for published reports using the terms BRCA1, breast cancer, basal-like, chemotherapy, prognosis, and predictive markers. In some cases, due to the restriction of space, readers are referred to review articles to allow further reading. Only articles published in English were included.

Original languageEnglish
Pages (from-to)142-150
Number of pages9
JournalThe Oncologist
Issue number2
Publication statusPublished - Feb 2007

ASJC Scopus subject areas

  • Cancer Research
  • Hematology


Dive into the research topics of 'BRCA1, a potential biomarker in the treatment of breast cancer'. Together they form a unique fingerprint.

Cite this